Significant Improvement in IBD Medication Adherence Reported by Johns Hopkins, Curant Health

Significant Improvement in IBD Medication Adherence Reported by Johns Hopkins, Curant Health
A collaborative project between researchers at Johns Hopkins University’s Meyerhoff Inflammatory Bowel Disease Center and Curant Health has produced the first study to report long-term adherence data for Crohn's disease and ulcerative colitis. Adherence refers to a patient's compliance for taking medications as prescribed by their physician. Project ALIVE (Adherence and Long-term IBD Value-added Effectiveness) was initiated in 2014 with the goal of implementing and evaluating the effectiveness of an IBD medication therapy management (MTM) model and comparing it to the current clinical standard of care in a large university hospital setting. The two-year partnership has resulted in preliminary findings showing that Project ALIVE’s MTM model improved adherence by more than 30 percent compared to the standard of care for IBD patients. The results have significant clinical implication because past research shows that poor IBD adherence to medication may lead to more frequent relapses, a disabling disease course, and an increased risk for colorectal cancer. The findings were presented via poster at the 2016 American College of Gastroenterology Annual Scientific Meeting Oct. 14-19 in Las Vegas. The presentation includes data from Project ALIVE’s randomized control trial that enrolled 110 subjects with either ulcerative colitis or Crohn's disease. Most su
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *